Eli Lilly, a prominent weight-loss drug manufacturer, experienced a decline in its market share in India, falling from 61% in February to 56% in March. This shift follows the expiration of the patent for semaglutide, a key ingredient in weight-loss medications, which allowed generic alternatives to enter the market. In contrast, rival Novo Nordisk maintained its market share at 25%. The Pharmarack report indicates that 13 Indian pharmaceutical companies have launched 26 brands of semaglutide, which is used for both weight loss and diabetes management. Experts predict that Eli Lilly's sales, particularly of its more expensive tirzepatide-based products, will continue to suffer as cheaper options proliferate. Eli Lilly's Mounjaro is priced at around ₹13,800 ($148) per month, making it significantly more expensive than Novo's offerings and substantially higher than the generic versions available. With 100 million diabetics and 125 million pre-diabetics in India, the market for these drugs is substantial, highlighting the competitive landscape for weight-loss solutions.